Krka, d.d., Novo mesto Krka-Farma d.o.o. Synthon B.V. Synthon Hispania S.L.
PolandAll drugs from this manufacturer
-
The medicine is used to treat chronic myeloid leukemia (CML) in adults, adolescents, and children at least 1 year of age. It is also used to treat Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and in the blast crisis phase of CML in adults for whom previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 20 mg ATC: L01EA02
-
It is used in the treatment of chronic myeloid leukemia (CML) in adults, adolescents, and children over 1 year of age. It is also used in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and in some cases of lymphoblastic blast crisis of CML.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 50 mg ATC: L01EA02
-
The medicine is used in adults, adolescents, and children (over 1 year of age) for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). It is also used in the treatment of blast crisis of CML in adults for whom previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 70 mg ATC: L01EA02
-
This medicine is used in adults, adolescents, and children (over 1 year of age) for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). It is also used in the treatment of blast crisis of CML in adults for whom previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 80 mg ATC: L01EA02
-
The medicine is used in adults, adolescents, and children (over 1 year of age) for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). In adults, it is also used to treat the lymphoblastoid blast crisis phase of CML if previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 100 mg ATC: L01EA02
-
The medicine is used to treat chronic myeloid leukemia (CML) in adults, adolescents, and children at least 1 year of age. It is also used to treat Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and in the blast crisis phase of CML in adults for whom previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 140 mg ATC: L01EA02